Which is in clinical trials in patients with cancer currently.

ARIAD presents AP26113 investigational ALK inhibitor preclinical research data in AACR annual meeting ARIAD Pharmaceuticals, Inc. today announced outcomes of preclinical research on its investigational anaplastic lymphoma kinase inhibitor – AP26113 – showing potent inhibition of the mark proteins and of mutant forms that are resistant to the first-generation ALK inhibitor, which is in clinical trials in patients with cancer currently. ARIAD scientists shown these data today at the annual conference of the American Association for Tumor Analysis in Washington, D.C.Globally, females account for over fifty % of the more than 35 million people living with HIV/AIDS. In sub-Saharan Africa, six out of 10 fresh HIV infections in adults occur in ladies. In a number of southern African countries, youthful females aged 15 to 24 are up to eight instances much more likely than their male peers to be contaminated with HIV. Among females, unprotected sex with an infected male partner continues to be the primary risk element for HIV infection, and in many parts of the world, heterosexual intercourse may be the driving pressure of the epidemic. Ladies are twice as most likely as their male companions to acquire HIV during sex. Although consistent and correct use of male condoms has been proven to prevent HIV infection, often women cannot choose if they are used.

ABC News partcipates in total censorship to downplay racism against white Americans It has been weeks since Vester Lee Flanagan, also called Bryce Williams, shot and killed two previous co-workers – TV journalist Alison Parker, 24, and her cameraman Adam Ward, 27 – because they were doing a live record one morning for a small station in Roanoke, Virginia.